Literature DB >> 19549767

Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Erica L Carpenter1, Rosemarie Mick, Andrew J Rech, Gregory L Beatty, Theresa A Colligon, Myrna R Rosenfeld, David E Kaplan, Kyong-Mi Chang, Susan M Domchek, Peter A Kanetsky, Leslie A Fecher, Keith T Flaherty, Lynn M Schuchter, Robert H Vonderheide.   

Abstract

PURPOSE: Disturbed peripheral blood B-cell homeostasis complicates certain infections and autoimmune diseases, such as HIV and systemic lupus erythematosus, but has not been reported in cancer. This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers. EXPERIMENTAL
DESIGN: Flow cytometry was used to identify phenotypic differences in B cells from patients with melanoma and normal donors. In vitro stimulated B cells were assessed for responsiveness and also used as stimulators of allogeneic T cells in mixed lymphocyte reactions.
RESULTS: We show B-cell dysregulation in patients with advanced melanoma (n = 26) and other solid tumors (n = 13), marked by a relative and absolute loss of CD27+ (memory) B cells and associated with an aberrant systemic plasmacytosis. Functionally, B cells from patients with melanoma inefficiently up-regulated immunoregulatory molecules and weakly secreted cytokines in response to CD40 and toll-like receptor 9 agonists. Stimulated B cells from patients induced proliferation of alloreactive CD4+ T cells, but these T cells poorly secreted IFNgamma and interleukin-2. These effects were recapitulated by using purified normal donor CD27(neg) B cells in these same assays, linking the predominance of CD27(neg) B cells in patients with the observed functional hyporesponsiveness. Indeed, B-cell dysfunction in patients strongly correlated with the extent of loss of CD27+ B cells in peripheral blood.
CONCLUSIONS: Disturbed B-cell homeostasis is a previously unrecognized feature of patients with advanced melanoma and other cancers and may represent an unanticipated mechanism of immune incompetence in cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549767      PMCID: PMC2896505          DOI: 10.1158/1078-0432.CCR-09-0537

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Reciprocal regulation of polarized cytokine production by effector B and T cells.

Authors:  D P Harris; L Haynes; P C Sayles; D K Duso; S M Eaton; N M Lepak; L L Johnson; S L Swain; F E Lund
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

Review 2.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

3.  Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients.

Authors:  Jianhua Ni; Edgardo Hembrador; Adrian M Di Bisceglie; Ira M Jacobson; Andrew H Talal; David Butera; Charles M Rice; Thomas J Chambers; Lynn B Dustin
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

4.  Loss of memory (CD27) B lymphocytes in HIV-1 infection.

Authors:  A De Milito; C Mörch; A Sönnerborg; F Chiodi
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

5.  Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.

Authors:  M Odendahl; A Jacobi; A Hansen; E Feist; F Hiepe; G R Burmester; P E Lipsky; A Radbruch; T Dörner
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

6.  Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function.

Authors:  Angela Malaspina; Susan Moir; Shyamasundaran Kottilil; Claire W Hallahan; Linda A Ehler; Shuying Liu; Marie A Planta; Tae-Wook Chun; Anthony S Fauci
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

7.  Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.

Authors:  Michael S von Bergwelt-Baildon; Robert H Vonderheide; Britta Maecker; Naoto Hirano; Karen S Anderson; Marcus O Butler; Zhinan Xia; Wan Y Zeng; Kai W Wucherpfennig; Lee M Nadler; Joachim L Schultze
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

8.  Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

Authors:  Karin Tarte; John De Vos; Thomas Thykjaer; Fenghuang Zhan; Geneviève Fiol; Valérie Costes; Thierry Rème; Eric Legouffe; Jean-François Rossi; John Shaughnessy; Torben F Ørntoft; Bernard Klein
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

9.  CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.

Authors:  Réjean Lapointe; Angélique Bellemare-Pelletier; Franck Housseau; Jacques Thibodeau; Patrick Hwu
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

10.  Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors.

Authors:  J Andrew Duty; Peter Szodoray; Nai-Ying Zheng; Kristi A Koelsch; Qingzhao Zhang; Mike Swiatkowski; Melissa Mathias; Lori Garman; Christina Helms; Britt Nakken; Kenneth Smith; A Darise Farris; Patrick C Wilson
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

View more
  22 in total

1.  Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.

Authors:  Hiroyoshi Doi; Tara K Iyer; Erica Carpenter; Hong Li; Kyong-Mi Chang; Robert H Vonderheide; David E Kaplan
Journal:  Hepatology       Date:  2012-01-19       Impact factor: 17.425

2.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

3.  Deceleration of glycometabolism impedes IgG-producing B-cell-mediated tumor elimination by targeting SATB1.

Authors:  Jiajing Liu; Yifan Li; Zhou Lu; Jie Gu; Yun Liang; Enyu Huang; Zhiming Wang; Hushan Zhang; Luman Wang; Dan Zhang; Hongxiu Yu; Ronghua Liu; Yiwei Chu
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

4.  B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies.

Authors:  Hans A Schlößer; Martin Thelen; Axel Lechner; Kerstin Wennhold; Maria A Garcia-Marquez; Sacha I Rothschild; Elena Staib; Thomas Zander; Dirk Beutner; Birgit Gathof; Ramona Gilles; Engin Cukuroglu; Jonathan Göke; Alexander Shimabukuro-Vornhagen; Uta Drebber; Alexander Quaas; Christiane J Bruns; Arnulf H Hölscher; Michael S Von Bergwelt-Baildon
Journal:  Oncoimmunology       Date:  2018-11-02       Impact factor: 8.110

5.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

6.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

7.  Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.

Authors:  Erica L Carpenter; Rosemarie Mick; Jens Rüter; Robert H Vonderheide
Journal:  J Transl Med       Date:  2009-11-11       Impact factor: 5.531

Review 8.  Pathways and therapeutic targets in melanoma.

Authors:  Emma Shtivelman; Michael Q A Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T Flaherty; David E Fisher
Journal:  Oncotarget       Date:  2014-04-15

9.  Generation and identification of tumor-evoked regulatory B cells.

Authors:  Arya Biragyn; Catalina Lee-Chang; Monica Bodogai
Journal:  Methods Mol Biol       Date:  2014

Review 10.  Melanoma: oncogenic drivers and the immune system.

Authors:  Niki Karachaliou; Sara Pilotto; Cristina Teixidó; Santiago Viteri; María González-Cao; Aldo Riso; Daniela Morales-Espinosa; Miguel Angel Molina; Imane Chaib; Mariacarmela Santarpia; Eduardo Richardet; Emilio Bria; Rafael Rosell
Journal:  Ann Transl Med       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.